Open Access Review

COVID-19 a global crisis: Features, complications and suggested treatments

by Mustafa M. Abo-Elela 1  and  Nermeen A. ElKasabgy 2,*
Hefny pharma group, Cairo, Egypt, Cairo, Egypt
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
Author to whom correspondence should be addressed.
IJCMR  2023, 7; 1(2), 7;
Received: 15 July 2023 / Accepted: 22 August 2023 / Published Online: 25 August 2023


Coronavirus disease 2019 (COVID-19); caused by the novel coronavirus (SARS-CoV-2) is the talk of everyone all over the world in 2020 since it has been considered as a public health emergency of international concern by WHO in 30th January, 2020. COVID-19 is a highly transmittable disease with different symptoms which can vary from mild to severe and life threatening. Scientists all over the world are working on finding a treatment or vaccine for this disease. All of these studies are currently not finished yet during writing this review. However, in this review a summary about the current status of these studies is given. This summary includes medicinal plants and natural products, antivirals like remdesivir, favipiravir, oseltamivir and nelfinavir as well as other miscellaneous drugs like chloroquine, hydroxychloroquine and ivermectin which showed promising results in treating COVID-19. In conclusion, the review recommends conducting further investigations worldwide and reporting them in peer-reviewed publications to aid in improving the drugs’ dosing regimens and clinical studies.

Copyright: © 2023 by M. Abo-Elela and A. ElKasabgy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Share and Cite

ACS Style
M. Abo-Elela, M.; A. ElKasabgy, N. COVID-19 a global crisis: Features, complications and suggested treatments. International Journal of Clinical Medical Research, 2023, 1, 7.
AMA Style
M. Abo-Elela M, A. ElKasabgy N. COVID-19 a global crisis: Features, complications and suggested treatments. International Journal of Clinical Medical Research; 2023, 1(2):7.
Chicago/Turabian Style
M. Abo-Elela, Mustafa; A. ElKasabgy, Nermeen 2023. "COVID-19 a global crisis: Features, complications and suggested treatments" International Journal of Clinical Medical Research 1, no.2:7.

Article Metrics

Article Access Statistics


  1. WHO. SARS (Severe Acute Respiratory Syndrome). [cited 2020 18th May]; Available from:
  2. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2020 18th May]; Available from:
  3. Sifuentes-Rodríguez E, Palacios-Reyes D. COVID-19: The outbreak caused by a new coronavirus. Boletin Medico del Hospital Infantil de Mexico. 2020; 77(2): 47-53.
  4. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection, Genetics and Evolution. 2020; 79: 104212.
  5. WHO. WHO Timeline - COVID-19. [cited 2020 18th May]; Available from:
  6. ICTV. International Committee on Taxonomy of Viruses
  7. ICTV. [cited 2020 19th May]; Available from:
  8. NLH. Coronaviruses. [cited 2020 18th May]; Available from:
  9. Worldometer. Countries where COVID-19 has spread. [cited 2020 21st May]; Available from:
  10. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. [cited 2020 19th May]; Available from:
  11. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2020 19th May]; Available from:
  12. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of advanced research. 2020; 24: 91-8.
  13. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. Jama. 2020.
  14. WBNG.COM. Cross-contamination: How a touch-and-go lifestyle can increase your risk for COVID-19. [cited 2020 3rd May]; Available from:
  15. Cheng VC, Wong S-C, Chen JH, Yip CC, Chuang VW, Tsang OT, et al. Escalating infection control response to the rapidly evolving epidemiology of the Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infection Control & Hospital Epidemiology. 2020: 1-6.
  16. Jiatong S, Wenjun L. COVID‐19 epidemic: disease characteristics in children. Journal of Medical Virology. 2020.
  17. CDC. Pregnancy and Breastfeeding. [cited 2020 4th May]; Available from:
  18. CDC. Symptoms of Coronavirus. [cited 2020 4th May]; Available from:
  19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497-506.
  20. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395(10223): 507-13.
  21. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang Z-J. Novel coronavirus infection in hospitalized infants under 1 year of age in China. Jama. 2020; 323(13): 1313-4.
  22. She J, Liu W. Epidemiological characteristics and prevention and control measures of Corona Virus Disease 2019 in children. Luzhou, China: Department of Pediatrics, Southwest Medical University. 2020.
  23. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020; 395(10223): 514-23.
  24. Cai J, Wang X, Ge Y, Xia A, Chang H, Tian H, et al. First case of 2019 novel coronavirus infection in children in Shanghai. Zhonghua er ke za zhi= Chinese journal of pediatrics. 2020; 58: E002.
  25. ECDC. Q & A on COVID-19. [cited 2020 17th May]; Available from:
  26. UNDP. The Social and Economic Impact of Covid-19 in the Asia-Pacific Region. [cited 2020 4th May]; Available from:
  27. CDC. World Map. [cited 2020 21st May]; Available from:
  28. IBRD-IDA. The World Bank Group Moves Quickly to Help Countries Respond to COVID-19. [cited 2020 21st May]; Available from:
  29. WHO. Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine
  30. [cited 2020 4th May]; Available from:
  31. Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19: 305-6.
  32. Biopharma. CEPI Extends Collaboration With Novavax To Advance Development and Manufacture of COVID-19 Vaccine. [cited 2020 17th May]; Available from:
  33. CEPI. CEPI launches new funding opportunity to accelerate COVID-19 vaccine development and production. [cited 2020 17th May]; Available from:
  34. NPR. The Coronavirus Crisis. [cited 2020 17th May]; Available from:
  35. Naithani R, Mehta RG, Shukla D, Chandersekera SN, Moriarty RM. Antiviral activity of phytochemicals: a current perspective. Dietary Components and Immune Function: Springer; 2010. p. 421-68.
  36. Cecílio AB, de Faria DB, de Carvalho Oliveira P, Caldas S, de Oliveira DA, Sobral MEG, et al. Screening of Brazilian medicinal plants for antiviral activity against rotavirus. Journal of ethnopharmacology. 2012; 141(3): 975-81.
  37. Chiow K, Phoon M, Putti T, Tan BK, Chow VT. Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection. Asian Pacific journal of tropical medicine. 2016; 9(1): 1-7.
  38. Im K, Kim J, Min H. Ginseng, the natural effectual antiviral: protective effects of Korean Red Ginseng against viral infection. Journal of ginseng research. 2016; 40(4): 309-14.
  39. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. The Lancet. 2003; 361(9374): 2045-6.
  40. Wen C-C, Kuo Y-H, Jan J-T, Liang P-H, Wang S-Y, Liu H-G, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. Journal of medicinal chemistry. 2007; 50(17): 4087-95.
  41. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study. Prepr doi10 20944/preprints202003 0226 v1. 2020: 1-14.
  42. Rezaei R, Aslani S, Marashi M, Rezaei F, Sharif-Paghaleh E. Immunomodulatory Effects of Vitamin D in Influenza Infection. Current Immunology Reviews. 2018; 14(1): 40-9.
  43. Bikle D. Vitamin D: production, metabolism, and mechanisms of action. Endotext [Internet]: MDText. com, Inc.; 2017.
  44. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. The Journal of clinical investigation. 1985; 76(4): 1536-8.
  45. Berry DJ, Hesketh K, Power C, Hyppönen E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. British Journal of Nutrition. 2011; 106(9): 1433-40.
  46. Cannell J, Vieth R, Umhau J, Holick M, Grant W, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiology & Infection. 2006; 134(6): 1129-40.
  47. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Archives of internal medicine. 2009; 169(4): 384-90.
  48. Dancer RC, Parekh D, Lax S, D'Souza V, Zheng S, Bassford CR, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015; 70(7): 617-24.
  49. Khare D, Godbole NM, Pawar SD, Mohan V, Pandey G, Gupta S, et al. Calcitriol [1, 25 [OH] 2 D3] pre-and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. European journal of nutrition. 2013; 52(4): 1405-15.
  50. Parlak E, Ertürk A, Çağ Y, Sebin E, Gümüşdere M. The effect of inflammatory cytokines and the level of vitamin D on prognosis in Crimean-Congo hemorrhagic fever. International journal of clinical and experimental medicine. 2015; 8(10): 18302.
  51. SciTechDaily. This may be because vitamin D is important in regulation and suppression of the inflammatory cytokine response, which causes the severe consequences of COVID-19 and ‘acute respiratory distress syndrome’ associated with ventilation and death. [cited 2020 16th May]; Available from:
  52. Daneshkhah A, Eshein A, Subramanian H, Roy HK, Backman V. The Role of Vitamin D in Suppressing Cytokine Storm in COVID-19 Patients and Associated Mortality. MedRxiv. 2020.
  53. Rhodes JM, Subramanian S, Laird E, Anne Kenny R. low population mortality from COVID‐19 in countries south of latitude 35 degrees North–supports vitamin D as a factor determining severity. Alimentary pharmacology & therapeutics. 2020.
  54. Marik PE, Kory P, Varon J. Does vitamin D status impact mortality from SARS-CoV-2 infection? Medicine in Drug Discovery. 2020.
  55. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research. 2020; 7(1): 1-10.
  56. Pharmacists ASoH-S. Assessment of Evidence for COVID-19-Related Treatments: Updated 5/8/2020. [cited 2020 09 May]; Available from:
  57. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública. 2020; 44: e40.
  58. Agency EM. Summary on compassionate use. [cited 2020 09 May]; Available from:
  59. FDA. Emergency Use Authorization (EUA) for emergency use of remdesivir for the treatment of
  60. hospitalized 2019 coronavirus disease (COVID-19) patients. [cited 2020 9th May]; Available from:
  61. Cao Y-c, Deng Q-x, Dai S-xJTM, Disease I. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. 2020: 101647.
  62. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020.
  63. Medicine. USNLo. . [cited 2020 09 May]; Available from:
  64. NLH. NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. [cited 2020 18th May]; Available from:
  65. Gilead. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19. [cited 2020 18th May]; Available from:
  66. CDC. Avigan tablets 200 mg. [cited 2020 9th May]; Available from:
  67. Shiraki K, Daikoku TJP, therapeutics. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. 2020: 107512.
  68. Agency PaMD. Report on the Deliberation Results [cited 2020 09 May]; Available from:
  69. Nguyen THT, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet A-M, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. 2017; 11(2): e0005389.
  70. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.
  71. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020.
  72. TAMIFLU® (oseltamivir phosphate). 2012 [cited 2020 9 May]; Available from:
  73. Davies BEJJoac. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. 2010; 65(suppl_2): ii5-ii10.
  74. He G, Massarella J, Ward PJCp. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. 1999; 37(6): 471-84.
  75. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochemical and biophysical research communications. 2004; 318(3): 719-25.
  76. Belubbi T, Shevade S, Dhawan V, Sridhar V, Majumdar A, Nunes R, et al. Lipid Architectonics for Superior Oral Bioavailability of Nelfinavir Mesylate: Comparative in vitro and in vivo Assessment. AAPS PharmSciTech. 2018; 19(8): 3584-98.
  77. Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. The Pediatric infectious disease journal. 2003; 22(1): 48-55.
  78. CSH. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. [cited 2020 17th May]; Available from:
  79. CSH. The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections. [cited 2020 17th May]; Available from:
  81. Winzeler EA. Malaria research in the post-genomic era. Nature. 2008; 455(7214): 751-6.
  82. Parhizgar AR, Tahghighi A. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iranian journal of medical sciences. 2017; 42(2): 115.
  83. White N, Pukrittayakamee S, Hien T, Faiz M, Mokuolu O, Dondorp A. Malaria. Lancet [Internet]. 2014; 383 (9918): 723–35.
  84. Frisk-Holmberg M, Bergqvist Y, Englund U. Chloroquine intoxication. British journal of clinical pharmacology. 1983; 15(4): 502.
  85. Lee S-J, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nature Reviews Nephrology. 2011; 7(12): 718.
  86. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International journal of antimicrobial agents. 2007; 30(4): 297-308.
  87. Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. Journal of clinical virology. 2001; 20(3): 137-40.
  88. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases. 2003; 3(11): 722-7.
  89. Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrobial agents and chemotherapy. 2009; 53(8): 3416-21.
  90. Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral research. 2018; 149: 143-9.
  91. Yan Y, Zou Z, Sun Y, Li X, Xu K-F, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell research. 2013; 23(2): 300-2.
  92. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza and other respiratory viruses. 2007; 1(5‐6): 189-92.
  93. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. The Lancet Infectious diseases. 2011; 11(9): 677-83.
  94. Peymani P, Yeganeh B, Sabour S, Geramizadeh B, Fattahi MR, Keyvani H, et al. New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial). Canadian journal of physiology and pharmacology. 2016; 94(6): 613-9.
  95. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and biophysical research communications. 2004; 323(1): 264-8.
  96. Li R, Qiao S, Zhang G. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. Journal of Infection. 2020; 80(4): 469-96.
  97. Feldman N. Possible treatment for COVID-19 enters clinical trial at Penn. 2020 [cited 2020 6th April]; Available from:
  98. Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion. Virology. 2011; 413(2): 265-74.
  99. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020.
  100. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. The American journal of medicine. 1983; 75(1): 11-8.
  101. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clinical reviews in allergy & immunology. 2012; 42(2): 145-53.
  102. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996; 5 Suppl 1: S11-5.
  103. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. International ophthalmology clinics. 1999; 39(2): 49-57.
  104. Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018; 14(8): 1435-55.
  105. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. The Lancet infectious diseases. 2006; 6(2): 67-9.
  106. FDA. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or
  107. Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment
  108. of 2019 Coronavirus Disease [cited 2020 6th April]; Available from:
  109. BENDER K. Results from a Controlled Trial of Hydroxychloroquine for COVID-19. 2020 [cited 2020 6th April]; Available from:
  110. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020: 105949.
  111. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020.
  112. Canga AG, Prieto AMS, Liébana MJD, Martínez NF, Vega MS, Vieitez JJG. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. The AAPS journal. 2008; 10(1): 42-6.
  113. Götz V, Magar L, Dornfeld D, Giese S, Pohlmann A, Höper D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Scientific reports. 2016; 6(1): 1-15.
  114. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal. 2012; 443(3): 851-6.
  115. Baraka O, Mahmoud B, Marschke C, Geary T, Homeida M, Williams J. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. European journal of clinical pharmacology. 1996; 50(5): 407-10.
  116. Marty FM, Lowry CM, Rodriguez M, Milner DA, Pieciak WS, Sinha A, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clinical Infectious Diseases. 2005; 41(1): e5-e8.
  117. Zeng Z, Andrew N, Arison B, Luffer-Atlas D, Wang R. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998; 28(3): 313-21.
  118. Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen®-based assay for high-throughput screening for specific inhibitors of nuclear import. Journal of biomolecular screening. 2011; 16(2): 192-200.
  119. Tay M, Fraser JE, Chan W, Moreland NJ, Rathore AP, Wang C, et al. Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral research. 2013; 99(3): 301-6.
  120. Wulan WN, Heydet D, Walker EJ, Gahan ME, Ghildyal R. Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses. Frontiers in microbiology. 2015; 6: 553.
  121. Wurm T, Chen H, Hodgson T, Britton P, Brooks G, Hiscox JA. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. Journal of virology. 2001; 75(19): 9345-56.
  122. Hiscox JA, Wurm T, Wilson L, Britton P, Cavanagh D, Brooks G. The coronavirus infectious bronchitis virus nucleoprotein localizes to the nucleolus. Journal of virology. 2001; 75(1): 506-12.
  123. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020: 104787.